F-1/A: Scinai Immunotherapeutics Eyes $10 Million Capital Injection via Standby Equity Agreement with YA II PN, Ltd.

Scinai Immunotherapeutics aims to bolster its financial position through a standby equity purchase agreement, potentially raising up to $10 million by offering American Depositary Shares (ADSs) to YA II PN, Ltd.

Summary

• Scinai Immunotherapeutics has filed a registration statement for the offer and sale of up to 3,022,796 American Depositary Shares (ADSs) by YA II PN, Ltd.
• These ADSs represent 12,091,184,000 Ordinary Shares.
• The Ordinary Shares are to be issued pursuant to a Standby Equity Purchase Agreement dated March 3, 2025, with YA.
• Scinai will not receive any proceeds from the sale of ADSs by YA, but may receive up to $10.0 million in aggregate gross proceeds from sales of ADSs to YA.
• As consideration for YA's commitment, Scinai will issue 28,784 ADSs to YA in two equal installments.
• The additional 2,994,012 ADSs would be purchased by YA from time to time at a price equal to 97% of the lowest of the three daily volume weighted average prices (VWAPs) during a pricing period.
• The Selling Shareholder will pay all brokerage fees and commissions.
• Scinai will pay the expenses incurred in registering the offer and sale of the shares.
• As of March 10, 2025, the last reported sale price of the ADSs on Nasdaq was $3.28 per ADS.
• Investing in Scinai's securities involves a high degree of risk.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the agreement provides a potential source of funding, it also carries risks of dilution and dependence on market conditions.

Positives

• The Purchase Agreement, if fully utilized, is intended to provide Scinai with capital sufficient to fund its operations for at least the next 12 months.
• YA has agreed not to engage in short sales or hedging transactions with respect to ADSs during the term of the Purchase Agreement.

Negatives

• Scinai will not receive any proceeds from the sale of ADSs by the Selling Shareholder.
• The actual amount of proceeds that Scinai may receive cannot be determined at this time and will depend on the number of ADSs it sells under the Purchase Agreement and market prices at the times of such sales.
• There is no assurance that Scinai will be able to utilize the Purchase Agreement to the full extent.
• The resale by YA of a significant amount of shares registered for resale in this offering at any given time, or the perception that these sales may occur, could cause the market price of the ADSs to decline and to be highly volatile.

Risks

• Scinai is a developmental stage biopharmaceutical company with a history of operating losses.
• The company will require substantial additional financing to achieve its goals.
• Failure to meet Nasdaq's continued listing requirements could result in delisting.
• The company's business strategy may not be successful.
• Raising additional capital may cause dilution to existing shareholders.
• Clinical trials are very expensive, time-consuming, and difficult to implement.
• Positive results from earlier preclinical data and clinical trials may not be predictive of later clinical trials.
• The company faces significant competition.
• A disruption to the company's GMP biologics manufacturing facility in Jerusalem could impede its ability to advance its NanoAbs programs and deliver its CDMO services.

Future Outlook

The company expects that any proceeds received by it from such sales of ADSs under the Purchase Agreement will be used continued development of its pipeline products, as well as the advancement of new programs, business development activities, and general corporate purposes.

Industry Context

The announcement reflects a common strategy for biotech companies to secure funding for ongoing research and development. The use of standby equity purchase agreements provides flexibility but also carries risks of dilution for existing shareholders.

Comparison to Industry Standards

• Similar agreements are used by other companies in the biotech industry, such as Mustang Bio and Cellectar Biosciences, to access capital.
• The terms of the agreement, including the discount on VWAP, are typical for this type of financing.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new ADSs.
• The company's ability to fund its operations and advance its pipeline products may be improved.
• The market price of the ADSs could be affected by sales of shares by YA.

Next Steps

• Scinai may issue Advance Notices to YA to purchase ADSs.
• YA may sell the ADSs in the market.
• Scinai will use any proceeds received from sales of ADSs under the Purchase Agreement for continued development of its NanoAbs program, support of its CDMO business, and general corporate purposes.

Key Dates